Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798897 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
A Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Marker Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
- 7
- Study locations
NCT05798897 is a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by Marker Therapeutics. The registered enrollment target is 79 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (48% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05798897, a Phase 1 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by Marker Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Conditions Studied
Interventions
- DRUG MT-601
Study Locations (7)
Colorado
- University of Colorado - Aurora
- Colorado Blood Cancer Institute (Sarah Cannon) - Denver
California
- City of Hope - Duarte
Kansas
- University of Kansas Medical Center - Kansas City
New York
- Cornell - New York
Texas
- Sarah Cannon Research Institute at St. David's South Austin - Austin
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2023-01-02 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05798897
The ClinicalTrials.gov registry entry for NCT05798897 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (48% lower). The listed sponsor is Marker Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which MT-601 is the first listed.
NCT05798897 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Colorado, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT05798897 about?
NCT05798897 is a clinical study titled "Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma". This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
What is the current status of trial NCT05798897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2023-01-02. Estimated completion is 2028-02-28.
What conditions does trial NCT05798897 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory.
What interventions are being tested in trial NCT05798897?
The interventions under investigation include: MT-601 (DRUG).
Who is sponsoring clinical trial NCT05798897?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05798897 being conducted?
This trial has 7 study locations across California, Colorado, Kansas, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.